Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.

Bai M, Yang Z, Qi X, Fan D, Han G.

J Gastroenterol Hepatol. 2013 May;28(5):783-92. doi: 10.1111/jgh.12142.

PMID:
23425108
[PubMed - indexed for MEDLINE]
2.

Probiotics for patients with hepatic encephalopathy.

McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC.

Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008716. doi: 10.1002/14651858.CD008716.pub2. Review.

PMID:
22071855
[PubMed - indexed for MEDLINE]
3.

L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.

Jiang Q, Jiang XH, Zheng MH, Chen YP.

J Gastroenterol Hepatol. 2009 Jan;24(1):9-14. doi: 10.1111/j.1440-1746.2008.05582.x. Epub 2008 Sep 24.

PMID:
18823442
[PubMed - indexed for MEDLINE]
4.

A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.

Soárez PC, Oliveira AC, Padovan J, Parise ER, Ferraz MB.

Arq Gastroenterol. 2009 Jul-Sep;46(3):241-7. Review.

PMID:
19918694
[PubMed - indexed for MEDLINE]
Free Article
5.

Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.

Abid S, Jafri W, Mumtaz K, Islam M, Abbas Z, Shah HA, Hamid S.

J Coll Physicians Surg Pak. 2011 Nov;21(11):666-71. doi: 11.2011/JCPSP.666671.

PMID:
22078345
[PubMed - indexed for MEDLINE]
6.

A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.

Schmid M, Peck-Radosavljevic M, König F, Mittermaier C, Gangl A, Ferenci P.

Liver Int. 2010 Apr;30(4):574-82. doi: 10.1111/j.1478-3231.2010.02213.x.

PMID:
20456040
[PubMed - indexed for MEDLINE]
7.

Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis.

Luo M, Li L, Lu CZ, Cao WK.

Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1250-7. doi: 10.1097/MEG.0b013e32834d1938.

PMID:
21971378
[PubMed - indexed for MEDLINE]
8.

Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.

Blanco Vela CI, Poo Ramírez JL.

Ann Hepatol. 2011 Jun;10 Suppl 2:S55-9.

PMID:
22228883
[PubMed - indexed for MEDLINE]
9.

A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.

Mittal VV, Sharma BC, Sharma P, Sarin SK.

Eur J Gastroenterol Hepatol. 2011 Aug;23(8):725-32. doi: 10.1097/MEG.0b013e32834696f5.

PMID:
21646910
[PubMed - indexed for MEDLINE]
10.

Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure.

Pérez Hernández JL, Higuera de la Tijera F, Serralde-Zúñiga AE, Abdo Francis JM.

Ann Hepatol. 2011 Jun;10 Suppl 2:S66-9. Review.

PMID:
22228885
[PubMed - indexed for MEDLINE]
11.

Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.

Poo JL, Góngora J, Sánchez-Avila F, Aguilar-Castillo S, García-Ramos G, Fernández-Zertuche M, Rodríguez-Fragoso L, Uribe M.

Ann Hepatol. 2006 Oct-Dec;5(4):281-8.

PMID:
17151582
[PubMed - indexed for MEDLINE]
12.

Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.

Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Krüger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rösch W, Stauch S.

Hepatology. 1997 Jun;25(6):1351-60.

PMID:
9185752
[PubMed - indexed for MEDLINE]
13.

[Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].

Hass HG, Nägele T, Seeger U, Hösl F, Gregor M, Kaiser S.

Z Gastroenterol. 2005 Apr;43(4):373-8. German.

PMID:
15830303
[PubMed - indexed for MEDLINE]
14.

Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.

Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Görtelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rösch W, Steffens J.

J Hepatol. 1998 May;28(5):856-64.

PMID:
9625322
[PubMed - indexed for MEDLINE]
15.

Ursodeoxycholic acid for primary biliary cirrhosis.

Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD000551. doi: 10.1002/14651858.CD000551.pub3. Review.

PMID:
23235576
[PubMed - indexed for MEDLINE]
16.

[Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].

Abdo-Francis JM, Pérez-Hernández JL, Hinojosa-Ruiz A, Hernández-Vásquez JR.

Rev Gastroenterol Mex. 2010;75(2):135-41. Spanish.

PMID:
20615780
[PubMed - indexed for MEDLINE]
17.

Nutritional support for liver disease.

Koretz RL, Avenell A, Lipman TO.

Cochrane Database Syst Rev. 2012 May 16;5:CD008344. doi: 10.1002/14651858.CD008344.pub2. Review.

PMID:
22592729
[PubMed - indexed for MEDLINE]
18.

Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy.

Ndraha S, Simadibrata M.

Acta Med Indones. 2010 Jul;42(3):158-61.

PMID:
20724770
[PubMed - indexed for MEDLINE]
Free Article
19.

Bezafibrate for primary biliary cirrhosis.

Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD009145. doi: 10.1002/14651858.CD009145.pub2. Review.

PMID:
22259000
[PubMed - indexed for MEDLINE]
20.

Bisphosphonates for osteoporosis in primary biliary cirrhosis.

Rudic JS, Giljaca V, Krstic MN, Bjelakovic G, Gluud C.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009144. doi: 10.1002/14651858.CD009144.pub2. Review.

PMID:
22161446
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk